Sai Parenterals Limited (SAIPARENT) announces acquisition of Bion Therapeutics' prescription business, adding 16 brands and enhancing market presence.
SMS Pharmaceuticals Limited (NSE: SMSPHARMA) reports a 30% YoY revenue growth and a 57% increase in PAT for Q2FY27, driven by strong volume growth and improv.
Marksans Pharma Limited (MARKSANS) reports record Q2 & H1 FY27 results with revenue crossing ₹900 crore and PAT nearly doubling.
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) reports Q2 FY27 growth, driven by portfolio transformation and innovation.
Kopran Limited (KOPRAN) shares Q2 2026-27 financial results, highlighting revenue growth and operational performance.
Sai Parenterals Limited (SAIPARENT) Q2 FY27 results show revenue up 9% QoQ, PAT grows 32.7% QoQ, ahead of FY27 targets.
CORONA Remedies Limited (CORONA) reports highest ever revenue with 22% growth for Q2FY27 on Y-o-Y basis, outperforming IPM.
Sanofi India Limited's board meeting concluded at 4:45 p.m. on October 29, 2026, with significant focus on strategic initiatives.
Senores Pharmaceuticals Limited (SENORES) reports Q2 FY27 revenue up 25% and EBITDA +38%, driven by strong performance across markets.
CORONA Remedies Limited (CORONA) receives ANVISA GMP certification for Bhayla manufacturing, reinforcing its commitment to 'One World, One Quality'.